265 related articles for article (PubMed ID: 6538948)
1. Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias).
Barbeau A
Neurotoxicology; 1984; 5(1):13-35. PubMed ID: 6538948
[TBL] [Abstract][Full Text] [Related]
2. The diagnosis of manganese-induced parkinsonism.
Cersosimo MG; Koller WC
Neurotoxicology; 2006 May; 27(3):340-6. PubMed ID: 16325915
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
[TBL] [Abstract][Full Text] [Related]
4. A synaptic mechanism underlying the behavioral abnormalities induced by manganese intoxication.
Calabresi P; Ammassari-Teule M; Gubellini P; Sancesario G; Morello M; Centonze D; Marfia GA; Saulle E; Passino E; Picconi B; Bernardi G
Neurobiol Dis; 2001 Jun; 8(3):419-32. PubMed ID: 11442351
[TBL] [Abstract][Full Text] [Related]
5. The enigma of neuromelanin in Parkinson's disease substantia nigra.
Youdim MB; Ben-Shachar D; Riederer P
J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
[TBL] [Abstract][Full Text] [Related]
6. Oxidative mechanisms in nigral cell death in Parkinson's disease.
Jenner P
Mov Disord; 1998; 13 Suppl 1():24-34. PubMed ID: 9613715
[TBL] [Abstract][Full Text] [Related]
7. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
8. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
10. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
Orzi F; Fornai F; Blandini F
Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
[No Abstract] [Full Text] [Related]
11. Dopamine transporter binding in chronic manganese intoxication.
Huang CC; Weng YH; Lu CS; Chu NS; Yen TC
J Neurol; 2003 Nov; 250(11):1335-9. PubMed ID: 14648150
[TBL] [Abstract][Full Text] [Related]
12. Role of manganese in dystonia.
Barbeau A; Inoué N; Cloutier T
Adv Neurol; 1976; 14():339-52. PubMed ID: 821321
[TBL] [Abstract][Full Text] [Related]
13. The neuropathology of manganese-induced Parkinsonism.
Perl DP; Olanow CW
J Neuropathol Exp Neurol; 2007 Aug; 66(8):675-82. PubMed ID: 17882011
[TBL] [Abstract][Full Text] [Related]
14. The effects of manganese on glutamate, dopamine and gamma-aminobutyric acid regulation.
Fitsanakis VA; Au C; Erikson KM; Aschner M
Neurochem Int; 2006; 48(6-7):426-33. PubMed ID: 16513220
[TBL] [Abstract][Full Text] [Related]
15. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
16. Manganese, melanins and the extrapyramidal system.
Cotzias GC
J Neurosurg; 1966 Jan; 24(1):Suppl:170-80. PubMed ID: 4955707
[No Abstract] [Full Text] [Related]
17. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
Youdim MB; Riederer P
J Neural Transm Suppl; 1993; 40():57-67. PubMed ID: 8294901
[TBL] [Abstract][Full Text] [Related]
18. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019
[TBL] [Abstract][Full Text] [Related]
19. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
[TBL] [Abstract][Full Text] [Related]
20. Manganese-enhanced MRI in a rat model of Parkinson's disease.
Pelled G; Bergman H; Ben-Hur T; Goelman G
J Magn Reson Imaging; 2007 Oct; 26(4):863-70. PubMed ID: 17896372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
